Leukemia in pregnancy

Validated data from which conclusions may be drawn about the management of leukemia during pregnancy are sparse. Cytotoxic agents should generally be avoided during the first trimester, when there is an approximately 17% chance of fetal malformation, particularly with folate antagonists. However, ac...

Full description

Saved in:
Bibliographic Details
Published inSeminars in oncology Vol. 27; no. 6; p. 667
Main Authors Brell, J, Kalaycio, M
Format Journal Article
LanguageEnglish
Published United States 01.12.2000
Subjects
Antineoplastic Agents - adverse effects
Female
Fetus - drug effects
Humans
Leukemia - therapy
Pregnancy
Pregnancy Complications, Neoplastic - therapy
Pregnancy Outcome
Prenatal Exposure Delayed Effects
Online AccessGet more information

Cover

More Information
Summary:Validated data from which conclusions may be drawn about the management of leukemia during pregnancy are sparse. Cytotoxic agents should generally be avoided during the first trimester, when there is an approximately 17% chance of fetal malformation, particularly with folate antagonists. However, acute leukemias demand prompt institution of cytotoxic chemotherapy to maximize the chances of maternal survival. Treatment beyond the first trimester is generally safe if appropriate monitoring and obstetric care are available. Treatment of chronic leukemias can usually be delayed until delivery without compromising maternal health. Treatment of leukemia during pregnancy does not appear to have a significant impact on the future growth and development of the child.
ISSN:0093-7754